Y.L. Verschoor

895 total citations · 2 hit papers
12 papers, 287 citations indexed

About

Y.L. Verschoor is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Y.L. Verschoor has authored 12 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 4 papers in Surgery. Recurrent topics in Y.L. Verschoor's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Genetic factors in colorectal cancer (5 papers). Y.L. Verschoor is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Genetic factors in colorectal cancer (5 papers). Y.L. Verschoor collaborates with scholars based in Netherlands, United States and Switzerland. Y.L. Verschoor's co-authors include Myriam Chalabi, Monique E. van Leerdam, Ton N. Schumacher, Steven J. Oosterling, Geerard L. Beets, Hendrik A. Marsman, Regina G. H. Beets‐Tan, Karolina Sikorska, J.B.A.G. Haanen and John B.A.G. Haanen and has published in prestigious journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Y.L. Verschoor

12 papers receiving 285 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

2022 129 citations Myriam Chalabi, Y.L. Verschoor et al. Annals of Oncology profile →
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

2024 40 citations Y.L. Verschoor, Sara Balduzzi et al. Nature Medicine profile →

Peers

Countries citing papers authored by Y.L. Verschoor

Since Specialization

Citations

This map shows the geographic impact of Y.L. Verschoor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y.L. Verschoor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y.L. Verschoor more than expected).

Fields of papers citing papers by Y.L. Verschoor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y.L. Verschoor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y.L. Verschoor. The network helps show where Y.L. Verschoor may publish in the future.

Co-authorship network of co-authors of Y.L. Verschoor

This figure shows the co-authorship network connecting the top 25 collaborators of Y.L. Verschoor. A scholar is included among the top collaborators of Y.L. Verschoor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y.L. Verschoor. Y.L. Verschoor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers 2025 ·Nature ·(unknown), Y.L. Verschoor, José G. van den Berg, Sara Balduzzi, Niels F. M. Kok, Marieke E. Ijsselsteijn, Kat Moore, Adham Jurdi, (unknown), (unknown), Monique E. van Leerdam, John B.A.G. Haanen, Emile E. Voest, Noel F.C.C. de Miranda, Ton N. Schumacher, Lodewyk F.A. Wessels, Myriam Chalabi	1
2	Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial breakdown → 2024 ·Nature Medicine ·(unknown), Y.L. Verschoor, (unknown), Sara Balduzzi, Hendrik A. Marsman, Marnix H. Geukes Foppen, Cecile Grootscholten, Simone Dokter, A.G. den Hartog, Wieke H.M. Verbeek, Karlijn Woensdregt, (unknown), Steven J. Oosterling, Ton N. Schumacher, Koert F.D. Kuhlmann, Regina G. H. Beets‐Tan, John B.A.G. Haanen, Monique E. van Leerdam, José G. van den Berg, Myriam Chalabi	40
3	503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study 2024 ·Annals of Oncology ·(unknown), Y.L. Verschoor, (unknown), Sara Balduzzi, (unknown), Cecile Grootscholten, Simone Dokter, A.G. den Hartog, Jacobus W. A. Burger, Wieke H.M. Verbeek, (unknown), Eduard R. Hendriks, Steven J. Oosterling, R.G.H. Beets-Tan, (unknown), J.B.A.G. Haanen, Koert F.D. Kuhlmann, Monique E. van Leerdam, José G. van den Berg, Myriam Chalabi	1
4	LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2 2024 ·Annals of Oncology ·Myriam Chalabi, (unknown), Y.L. Verschoor, Sara Balduzzi, (unknown), Niels F. M. Kok, (unknown), Cecile Grootscholten, Emile E. Voest, Jacobus W. A. Burger, Eduard R. Hendriks, Thomas R. de Wijkerslooth, (unknown), (unknown), Steven J. Oosterling, Arend G. J. Aalbers, José G. van den Berg, Monique E. van Leerdam, Ton N. Schumacher, J.B.A.G. Haanen	11
5	247P Radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: The TARZAN study 2024 ·Annals of Oncology ·(unknown), Y.L. Verschoor, Arend G. J. Aalbers, Doenja M. J. Lambregts, Baukelien van Triest, Femke P. Peters, Monique E. van Leerdam, Simone Dokter, Geerard L. Beets, Inge L. Huibregtse, R.G.H. Beets-Tan, Sara Balduzzi, Brechtje A. Grotenhuis, José G. van den Berg, Myriam Chalabi	2
6	LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study 2023 ·Annals of Oncology ·Y.L. Verschoor, (unknown), Sara Balduzzi, (unknown), Steven J. Oosterling, (unknown), (unknown), (unknown), Simone Dokter, Regina G. H. Beets‐Tan, (unknown), Geerard L. Beets, Monique E. van Leerdam, J.B.A.G. Haanen, Myriam Chalabi	16
7	Radiotherapy, atezolizumab, and bevacizumab in rectal cancers with the aim of organ preservation: The TARZAN study. 2023 ·Journal of Clinical Oncology ·Y.L. Verschoor, Doenja M. J. Lambregts, José van den Berg, Brechtje A. Grotenhuis, Arend G. J. Aalbers, Baukelien van Triest, Regina G. H. Beets‐Tan, (unknown), Simone Dokter, Sara Balduzzi, Emile E. Voest, John B.A.G. Haanen, Monique E. van Leerdam, Geerard L. Beets, Myriam Chalabi	3
8	1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study 2022 ·Annals of Oncology ·Myriam Chalabi, Y.L. Verschoor, Joris van de Haar, (unknown), Liudmila L. Kodach, Johanna van Sandick, Jolanda van Dieren, Sara Balduzzi, (unknown), (unknown), Koen J. Hartemink, Marieke A. Vollebergh, (unknown), Annemarieke Bartels‐Rutten, (unknown), Monique E. van Leerdam, Ton N. Schumacher, J.B.A.G. Haanen, Emile E. Voest	3
9	LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study breakdown → 2022 ·Annals of Oncology ·Myriam Chalabi, Y.L. Verschoor, (unknown), Karolina Sikorska, Geerard L. Beets, (unknown), (unknown), (unknown), (unknown), Hendrik A. Marsman, Eduard R. Hendriks, (unknown), (unknown), Steven J. Oosterling, Regina G. H. Beets‐Tan, Ton N. Schumacher, Monique E. van Leerdam, (unknown), J.B.A.G. Haanen	129
10	Persistent Borrelia burgdorferi Sensu Lato Infection after Antibiotic Treatment: Systematic Overview and Appraisal of the Current Evidence from Experimental Animal Models 2022 ·Clinical Microbiology Reviews ·Y.L. Verschoor, (unknown), René Spijker, Reinier M. van Hest, (unknown), (unknown), Anna J. Henningsson, Joppe W. Hovius	5
11	Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. 2022 ·Journal of Clinical Oncology ·Y.L. Verschoor, José van den Berg, Geerard L. Beets, Karolina Sikorska, Arend G. J. Aalbers, (unknown), Cecile Grootscholten, Inge L. Huibregtse, Hendrik A. Marsman, Steven J. Oosterling, (unknown), Marleen Kok, Ton N. Schumacher, Monique E. van Leerdam, John B.A.G. Haanen, Emile E. Voest, Myriam Chalabi	62
12	Neoadjuvant atezolizumab plus docetaxel/oxaliplatin/capecitabine in non-metastatic gastric and gastroesophageal junction adenocarcinoma: The PANDA trial. 2022 ·Journal of Clinical Oncology ·Y.L. Verschoor, Liudmila L. Kodach, José van den Berg, Johanna W. van Sandick, Jolanda van Dieren, Sara Balduzzi, Cecile Grootscholten, (unknown), Koen J. Hartemink, Marieke A. Vollebergh, (unknown), Annemarieke Bartels‐Rutten, (unknown), Monique E. van Leerdam, Ton N. Schumacher, Emile E. Voest, John B.A.G. Haanen, Myriam Chalabi	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact